Related Experiment Video
Updated: May 28, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Mechanisms of disease: hypertrophic cardiomyopathy
Norbert Frey1, Mark Luedde, Hugo A Katus
1Department of Cardiology and Angiology, University of Kiel, Schittenhelmstrasse 12, 24105 Kiel, Germany.
Insights
Hypertrophic cardiomyopathy (HCM) is a genetic heart disease causing thickened walls and arrhythmias. Research is clarifying molecular pathways to improve therapies for this common cause of sudden cardiac death.
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Background:
- Hypertrophic cardiomyopathy (HCM) is the most common monogenic inherited heart disease.
- It leads to left ventricular thickening, contractile dysfunction, and potentially fatal arrhythmias.
- HCM is the leading cause of sudden cardiac death in individuals under 35.
Purpose of the Study:
- To review the genetic basis of HCM, including over 900 mutations in 20 genes.
- To explore the unclear molecular events leading to the HCM clinical phenotype.
- To discuss potential pathological pathways for improved HCM therapies.
Main Methods:
- Review of genetic mutations in sarcomeric proteins (e.g., MYH7, MYBPC3, TNNT2).
- Discussion of proposed molecular pathways including calcium cycling, fibrosis, biomechanical stress, and energy homeostasis.
- Synthesis of current understanding to guide future therapeutic development.
Main Results:
- Identification of over 900 mutations in more than 20 genes, primarily encoding sarcomeric proteins.
- Elucidation of potential molecular mechanisms contributing to HCM pathogenesis.
- Highlighting the need for a deeper understanding of these pathways for targeted therapies.
Conclusions:
- Understanding the molecular mechanisms of HCM is crucial for developing effective and specific treatments.
- Investigating pathways like calcium handling, fibrosis, and energy metabolism is key.
- Improved knowledge will enhance therapeutic success for patients with hypertrophic cardiomyopathy.
Abstract:
Hypertrophic cardiomyopathy (HCM) is the most-common monogenically inherited form of heart disease, characterized by thickening of the left ventricular wall, contractile dysfunction, and potentially fatal arrhythmias. HCM is also the most-common cause of sudden cardiac death in individuals younger than 35 years of age. Much progress has been made in the elucidation of the genetic basis of HCM, resulting in the identification of more than 900 individual mutations in over 20 genes. Interestingly, most of these genes encode sarcomeric proteins, such as myosin-7 (also known as cardiac muscle β-myosin heavy chain; MYH7), cardiac myosin-binding protein C (MYBPC3), and cardiac muscle troponin T (TNNT2). However, the molecular events that ultimately lead to the clinical phenotype of HCM are still unclear. We discuss several potential pathways, which include altered calcium cycling and sarcomeric calcium sensitivity, increased fibrosis, disturbed biomechanical stress sensing, and impaired cardiac energy homeostasis. An improved understanding of the pathological mechanisms involved will result in greater specificity and success of therapies for patients with HCM.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure II: Pathophysiology
Cardiomyopathy I: Introduction and Classification
Pathophysiology of Heart Failure
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

